Skip to Content

A pilot phase II trial of Hypofractionated Intensity-modulated Radiotherapy (H-IMRT) combined with Temozolomide and Bavacizumab in patients with newly diagnosed GBM

Objective

Eligibility criteria include but are not limited to: 18 years
of age or older with newly diagnosed GBM (Glioblastoma Multiforme).

A screening period will occur to determine study eligibility. The total active treatment period is 6 months.

IRB Protocol Number
10-0274

All Other Trials

  • Brain & Nervous System

Cancer Trials

  • Brain and Nervous System Tumors
  • All Cancers
Contact
MONICA ROBISCHON at 720-848-0661
or MONICA.ROBISCHON@ucdenver.edu
Eligibility and Other Participant Information

Eligibility criteria include but are not limited to: 18 years
of age or older with newly diagnosed GBM (Glioblastoma Multiforme).